<DOC>
	<DOCNO>NCT00483938</DOCNO>
	<brief_summary>This study compare efficacy safety treatment pegylated-interferon alfa-2a plus ribavirin participant non-genotype 2/3 CHC , 12 week study treatment , undetectable hepatitis C virus ( HCV ) -ribonucleic acid ( RNA ) great equal ( &gt; = ) 2 log10 drop HCV-RNA . Participants randomize receive pegylated-interferon alfa-2a 180 microgram subcutaneously weekly plus ribavirin ( 1000-1400 milligram [ mg ] ) orally daily specify duration , follow 24 week treatment-free follow-up . Participants detectable HCV-RNA le ( &lt; ) 2 log10 drop HCV-RNA week 12 discontinue therapy .</brief_summary>
	<brief_title>The Individualized Management With Pegylated-interferon Alfa-2a ( Pegasys ) Ribavirin ( Copegus ) Offering Viral Eradication : A Study Pegylated-interferon Alfa-2a Plus Ribavirin Participants With Chronic Hepatitis C ( CHC ) Non-genotype 2/3 ( IMPROVE )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>evidence CHC ; evidence hepatitis C nongenotype 2 3 ; compensate liver disease . infection HCV genotype 2 3 ; history receive systemic antiviral therapy activity CHC &lt; =3 month prior start study ; hepatitis A , hepatitis B human immunodeficiency virus ( HIV ) infection ; history evidence medical condition associate chronic liver disease CHC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>